Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Biogen moves forward with aducanumab launch plans 

By Brian Buntz | April 22, 2021

BiogenBiogen’s (NSDQ:BIIB) Alzheimer’s drug aducanumab seemed to be a potential blockbuster until an FDA advisory committee voiced skepticism in November about the drug.

FDA reviewers had previously assessed the drug’s prospects more positively.

The company is preparing for the event of an FDA approval of the drug in June.

Biogen’s CEO Michel Vounatsos said in an analyst call today that he expects the antibody drug to sell well given the surging numbers of Alzheimer’s patients in the U.S. and elsewhere. “We anticipate if approved, there will be a large influx of patients,” Vounatsos concluded.

The company has argued that aducanumab slows disease progression in Alzheimer’s patients, which is a feat that no other FDA-approved drug can manage. But critics have argued that the company has failed to demonstrate that the drug is effective and have expressed concern over the drug’s potential to cause amyloid-related imaging abnormalities (ARIA).

Earlier this year, FDA announced that it had extended the review period for aducanumab by three months to June 7, 2021, and that it had requested additional data related to the antibody.

UBS analysts have speculated that FDA’s request for more information regarding the drug was related to safety questions.

In a March briefing note, UBS analysts concluded that senior FDA officials are likely overseeing the drug review given the drug candidate’s “high profile” and the “atypical regulatory process” involved.

Several financial analysts have concluded that the aducanumab has a roughly 50/50 chance at FDA approval. If the agency listens to feedback from the Peripheral and Central Nervous System Advisory Committee, it could recommend that Biogen launch a new Phase 3 trial of the drug.

The company has already launched two Phase 3 studies of the drug. Both were stopped early. One trial seemed to show no benefits from the drug, while the other indicated it was effective. After further reviewing the data, Biogen concluded that the patients receiving adequately high doses of aducanumab saw benefits in both clinical trials.

Aducanumab is similar to Eli Lilly’s donanemab in its amyloid in Alzheimer’s disease. Several pharmaceutical companies have been inspired by the amyloid hypothesis, which holds that the protein fragment beta-amyloid is toxic to the brain and is thus responsible for Alzheimer’s.

Donanemab, like aducanumab, has had mixed clinical trial data results to date.

Given the substantial Alzheimer’s patient population and shortage of treatments available for the disease, the Alzheimer’s Foundation has supported FDA approval of aducanumab.


Filed Under: clinical trials, Drug Discovery
Tagged With: Aducanumab, Alzheimer's disease, amyloid, Biogen, donanemab, Eli Lilly, FDA
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
How biosimulation and virtual trials can bust through clinical trial roadblocks
Complexity’s counterpoint: Understanding protocol optimization 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE